ライフサイエンスコーパス: surface antigen

1 nctional cure (confirmed loss of hepatitis B surface antigen).

2 r surface and post modified with hepatitis B surface antigen.

3 till far from achieving seroclearance of HBV surface antigen.

4 A of a known virulence factor, delta-amastin surface antigen.

5 inding specificity by the hemagglutinin (HA) surface antigen.

6 as primarily within the G protein, the major surface antigen.

7 cell-surface death receptor FS-7-associated surface antigen.

8 pansion was correlated with the titer of HBV surface antigen.

9 of monoclonal antibodies (mAb) against Treg surface antigens.

10 as diagnostic systems for various tumors and surface antigens.

11 ephalitis with antibodies targeting neuronal surface antigens.

12 he immune response directed toward invariant surface antigens.

13 ROR2 but not human ROR1 or other human cell-surface antigens.

14 odel of multivalent antibody binding to cell surface antigens.

15 loss of immune tolerance to nuclear and cell surface antigens.

16 romote viral release and is one of the major surface antigens.

17 r, which highlights the presence of cellular surface antigens.

18 ent or donor T cells to target specific cell-surface antigens.

19 ram an intact TCR complex to recognize tumor surface antigens.

20 on of specific epitopes within proteinaceous surface-antigens.

21 colonization factor antigen I (CFA/I), coli surface antigen 17 (CS17), or CS1, suggesting that the b

22 dy, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjuga

23 Using coli surface antigen 20 (CS20) fimbriae as a model ETEC colon

24 dence that serologic testing for hepatitis B surface antigen accurately identifies HBV infection.

25 in plasma and loss of detectable hepatitis B surface antigen after cessation of therapy.

26 /NTCP cells secreted very little hepatitis B surface antigen after infection with cell culture-derive

27 rri of complex target molecules such as cell surface antigens, allergens, and food contaminants.

28 (O-Ag) is known to limit antibody binding to surface antigens, although the relationship between anti

29 ALL leukemic cells express several surface antigens amenable to target therapies, including

30 5% (12/225) of them had positive hepatitis B surface antigen and 13.4% had past infection with hepati

31 k children at 1 year of age with hepatitis B surface antigen and anti-hepatitis B to identify those w

32 participants, and antibodies to hepatitis B surface antigen and antibodies to hepatitis B core antig

33 Another major surface antigen and autotransporter, rOmpB, exhibits a d

34 yte expansion, and expression of hepatitis B surface antigen and core antigen in liver tissues from 2

35 rs, the cumulative incidences of hepatitis B surface antigen and HBeAg seroclearance were 3.2% (n = 5

36 B viral infection by testing for hepatitis B surface antigen and the antibody to hepatitis B core ant

37 een the production of antibodies against WHV surface antigens and parameters of WHV infection appears

38 in genes responding to rsp, which regulates surface antigens and toxin production; agr, which regula

39 on sites can alter other properties of viral surface antigens and virions.

40 21,419 veterans with a positive hepatitis B surface antigen, and 97% of patients had alanine aminotr

41 ree sizes, collectively known as hepatitis B surface antigen, and adopts multiple conformations in th

42 o rapidly reduce serum HBV DNA and serum HBV surface antigen, and they promote the elimination of hep

43 rent AMA1 and MSP2 alleles of merozoites, IE surface antigens, and antibody functional activities wer

44 perhaps as functional oncogenes, biomarkers, surface antigens, and pharmacological targets.

45 eropositive for both antibody to hepatitis B surface antigen (anti-HBs) and anti-HBc (13 of 233 [5.6%

46 ave reported loss of antibody to hepatitis B surface antigen (anti-HBs) in a high proportion of perso

47 detection of antibodies against hepatitis B surface antigen (anti-HBs) in clinical serum samples usi

48 sons were tested for antibody to hepatitis B surface antigen (anti-HBs) levels 30 years after receivi

49 es about whether the antibody to hepatitis B surface antigen (anti-HBs) protects against reactivation

50 rent) infection; and antibody to hepatitis B surface antigen (anti-HBs), indicative of immunity from

51 of antibody against hepatitis B virus (HBV) surface antigen (anti-HBs), is undetermined.

52 any of HBV serological markers (hepatitis B surface antigen, anti-hepatitis B core antibodies, or HB

53 e-induced HBV immunity (antibody against HBV surface antigen; anti-HBs) in U.S. Hispanics/Latinos and

54 ere also HBsAg negative and anti-hepatitis B surface antigen antibody (anti-HBs) positive.

55 ver half (52.9%) had antibody to hepatitis B surface antigen antibody levels of <10 mIU/mL and there

56 ice 2: Clinicians should screen (hepatitis B surface antigen, antibody to hepatitis B core antigen, a

57 By targeting internalizing cell surface antigens, antibody-siRNA complexes provide a pos

58 oing search for additional gametocyte/gamete surface antigens, as well as antigens on the surfaces of

59 ed an overlength HBV genome-and expressed HB surface antigen at levels relevant to patients.

60 Immunodominant surface antigen B (IsaB) is a virulence factor that help

61 due to shared expression of most targetable surface antigens between normal and malignant T cells, p

62 HSPG2 (perlecan) protein as the cognate cell surface antigen bound by the antibody.

63 lin (Ig) or IgG, and antibody to hepatitis B surface antigen-but anticancer therapy should not be del

64 We efficiently isolated surface antigens by enzymatic cleavage, with a design of

65 s that recognized senescence-associated cell-surface antigens by FACS analysis and a newly developed

66 rial lipooligosaccharide (LOS), a major cell-surface antigen, can be correlated with inflammatory pot

67 In this study, we found that the cell surface antigen CD13, a multifunctional transmembrane mo

68 adoptive T cell therapies targeting the cell surface antigen CD19 has been demonstrated in hematopoie

69 maturation protein-1 (BLIMP-1), and the cell surface antigens CD38 and CD138/Syndecan-1.

70 n the major Plasmodium falciparum sporozoite surface antigen, circumsporozoite protein (CSP).

71 Thus, ALPPL2 belongs to a rare class of cell surface antigens classified as truly tumor specific and

72 (RR = 2.1, 95% CI 1.4-3.3), and hepatitis B surface antigen clearance (RR = 5.8, 95% CI 1.1-31.5).

73 R = 1.4, 95% CI 1.1-1.8) but not hepatitis B surface antigen clearance or seroconversion.

74 Antibodies targeting the NA surface antigen could also inhibit virus entry and egres

75 Cell surface antigen discovery is of great interest for biome

76 e family called var, which encodes the major surface antigen displayed on infected red blood cells (R

77 ze properties of the CTCs themselves such as surface antigens (e.g., epithelial cell adhesion molecul

78 specific antibodies after removal of the HBV surface antigen envelope demonstrated the association of

79 us (HBV) coinfection to provide HDV with HBV surface antigen envelope proteins.

80 gosaccharide structures to prevent access to surface antigen epitopes.

81 he C-terminal addition of a GPI-anchor (from surface antigen EtSAG1) mCherry was expressed on the spo

82 CS6, a prevalent surface antigen expressed in nearly 20% of clinical ente

83 tions, is frequently accomplished using cell surface antigens expressed by the cells of interest.

84 f immunoglobulin G antibodies targeting cell surface antigens expressed in multiple cGVHD affected ti

85 ozoites did not decline and antibodies to IE surface antigens expressing virulent phenotypes were muc

86 high sensitivity, allowing detection of low surface antigen-expressing cells linked to metastasis.

87 The surface antigen expression profiles of pretherapy and po

88 The OmpD surface antigen extraction was done from Salmonella typh

89 Greater numbers of the variant surface antigen families RIFIN, STEVOR, and PfMC-2TM wer

90 GPRC5D is a promising surface antigen for MM immunotherapy, and JNJ-64407564 i

91 target essentially any tumor-associated cell-surface antigen for which a monoclonal antibody can be m

92 eceptors that redirect polyclonal T cells to surface antigens for subsequent tumor elimination.

93 B core antigen, and antibody to hepatitis B surface antigen) for HBV in high-risk persons, including

94 Ehrlichia chaffeensis with the ompA, 17-kDa surface antigen gene, tsa56, msp2 (p44), and vlpt gene t

95 ribed by RNA polymerase I with the procyclin surface antigen genes expressed on trypanosome insect fo

96 ) site at amino acid residue 197 (N7) on the surface antigen gp120 of HIV-1 increases neutralization

97 (CD4i) transition state epitopes in the HIV surface antigen, gp120, while not exposed on free partic

98 pression of recombinant trypomastigote small surface antigen (gTSSA-I) in the eukaryote Leishmania ta

99 ntibodies in complex with viral glycoprotein surface antigens has greatly expanded our knowledge of t

100 Identification of tumor-specific cell surface antigens has proven challenging, as the vast maj

101 antibody specific for the CD20 B-lymphocyte surface antigen, has been increasingly adopted as a firs

102 ys that detect or measure serum levels of HB surface antigen, HB surface antibody, and HB core antibo

103 to significantly more decline in hepatitis B surface antigen, HBeAg, and HBV DNA (all P < 0.001).

104 us (HBV) DNA (</=2000 IU/mL) and hepatitis B surface antigen (HBsAg) (<1000 IU/mL) have been shown to

105 for prevalent diabetes comparing hepatitis B surface antigen (HBsAg) (+) to HBsAg (-) participants wa

106 Levels of antibody to hepatitis B surface antigen (HBsAg) (anti-HBs) and HBsAg-specific T-

107 is strategy, we investigated the hepatitis B surface antigen (HBsAg) and alpha-fetoprotein (AFP) with

108 to report seroprevalence of both hepatitis B surface antigen (HBsAg) and antibodies to HCV (anti-HCV)

109 Serologic HBV markers, including hepatitis B surface antigen (HBsAg) and e antigen (HBeAg), were test

110 All were positive for hepatitis B surface antigen (HBsAg) and HBeAg and had high levels of

111 Screening should include both hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (a

112 Therefore, the interaction of hepatitis B surface antigen (HBsAg) and KCs, and possible functional

113 ired toll-like receptor signaling by the HBV surface antigen (HBsAg) attenuates immune responses to f

114 e antigen (HBeAg)-seropositive, hepatitis B surface antigen (HBsAg) carrier children, who were follo

115 k factors were cohabitation with hepatitis B surface antigen (HBsAg) carriers, intravenous drug use,

116 ls in the process of hepatitis B virus (HBV) surface antigen (HBsAg) clearance and whether their phen

117 ion of hepatitis B viral DNA and hepatitis B surface antigen (HBsAg) concentrations occurs during the

118 Point-of-care tests for hepatitis B surface antigen (HBsAg) could be an ideal tool for a lar

119 34 RA patients who had available hepatitis B surface antigen (HBsAg) data, 123 patients positive for

120 Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) for its assembly and release.

121 Antibody-mediated clearance of hepatitis B surface antigen (HBsAg) from the circulation of chronica

122 les are formed from a single CSP-hepatitis B surface antigen (HBsAg) fusion protein, and this leads t

123 Here, we investigated hepatitis B surface antigen (HBsAg) genetic features underlying this

124 sispecies with reverse transcriptase and HBV surface antigen (HBsAg) heterogeneity in patients with a

125 pecific seroclearance pattern of hepatitis B surface antigen (HBsAg) in chronic hepatitis B virus (HB

126 dary outcomes were reductions in hepatitis B surface antigen (HBsAg) in control and experimental grou

127 epG2 cells, although very little hepatitis B surface antigen (HBsAg) is produced.

128 HBV RNA, HBV DNA, and hepatitis B surface antigen (HBsAg) levels as well as presence of HB

129 active hepatitis, correlating with high HBV surface antigen (HBsAg) levels.

130 ither anti-HBs seroconversion or hepatitis B surface antigen (HBsAg) loss.

131 lls, extracellular vesicles, and hepatitis B surface antigen (HBsAg) particles of hepatoma cell lines

132 A total of 42 hepatitis B surface antigen (HBsAg) positive, human immunodeficiency

133 d NIM811) on HBV replication and hepatitis B surface antigen (HBsAg) production in cell lines.

134 has implications for cancer development and surface antigen (HBsAg) production, but methods to quant

135 ommunity-based screening using a hepatitis B surface antigen (HBsAg) rapid test and subsequent HBV an

136 The log-reduction (LR) of surface antigen (HBsAg) reached a maximum value of 1.86

137 Model fits show that hepatitis B surface antigen (HBsAg) remained stable after a short ph

138 s in western Gambia were offered hepatitis B surface antigen (HBsAg) screening via a point-of-care te

139 The cumulative rates of hepatitis B surface antigen (HBsAg) seroclearance were 90% and 95% a

140 d the upper limit of normal, and hepatitis B surface antigen (HBsAg) seroclearance.

141 mans vaccinated with hepatitis B virus (HBV) surface antigen (HBsAg) sometimes develop humoral and ce

142 load, 7 had positive results on hepatitis B surface antigen (HBsAg) testing and had an undetectable

143 tients who had not yet completed hepatitis B surface antigen (HBsAg) testing were identified by a nov

144 o completed HBV core antibody (anti-HBc) and surface antigen (HBsAg) tests and 47,618 adults who comp

145 Using quantitative maternal surface antigen (HBsAg) to predict HBV infection in infa

146 r labeling was used to determine hepatitis B surface antigen (HBsAg) turnover rates in chronic hepati

147 mal immunization of mice against hepatitis B surface antigen (HBsAg) using a novel real-time controll

148 The serum gradient of hepatitis B surface antigen (HBsAg) varies over time after cessation

149 ES), the estimated prevalence of hepatitis B surface antigen (HBsAg) was 0.36% overall and 3.4% in no

150 women with reactive samples for hepatitis B surface antigen (HBsAg) were assessed with an SD BIOLINE

151 Immunoglobulin G (IgG) and Hepatitis B surface Antigen (HBsAg) were quantitatively analyzed wit

152 kers, including HBV "e" antigen (HBeAg), HBV surface antigen (HBsAg), and the antibody against HBsAg

153 atitis B and C markers including hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody

154 All were tested for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core an

155 9 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhancing the restoration of fu

156 okine measurements, quantitative hepatitis B surface antigen (HBsAg), HBeAg levels, HBV genotype, and

157 and hepatitis we identified all hepatitis B surface antigen (HBsAg), HBV DNA, and alanine aminotrans

158 uld be tested for HBV by 3 tests-hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti

159 ed on age-specific prevalence of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg),

160 ative of previous HBV infection; hepatitis B surface antigen (HBsAg), indicative of chronic (current)

161 ta from 2666 adults positive for hepatitis B surface antigen (HBsAg), infected with HBV genotypes B o

162 an immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), prevalent hepatic decompensatio

163 CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss after long-

164 lticenter trial and enrolled 118 hepatitis B surface antigen (HBsAg)- and hepatitis B e antigen-posit

165 ection (OBI), serum samples from hepatitis B surface antigen (HBsAg)-negative subjects <18 years enro

166 is B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative, antibody to hepatitis

167 Among HBV surface antigen (HBsAg)-positive HCC cases, 18/66 (27%)

168 lticenter, cohort study of 2,562 hepatitis B surface antigen (HBsAg)-positive individuals was conduct

169 hepatitis B virus (HBV) DNA for hepatitis B surface antigen (HBsAg)-positive participants, and antib

170 is B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-positive patients receiving ritu

171 leotide analogue treatment, were hepatitis B surface antigen (HBsAg)-positive with hepatitis B virus

172 ifier for determination of hepatitis B virus surface antigen (HBsAg).

173 cDNA, RNA, and expression of the hepatitis B surface antigen (HBsAg).

174 pregnant women are screened for hepatitis B surface antigen (HBsAg).

175 that reported prevalence of both hepatitis B surface antigen (HBsAg; prevalence of HBV infection) and

176 ntreated (25) or NUC treated (36 hepatitis B surface antigen [HBsAg](+) and 10 HBsAg(-)/hepatitis B s

177 ; anti-HBc), active HBV infection (serum HBV surface antigen; HBsAg), and vaccine-induced HBV immunit

178 HBV surface antigens (HBsAgs) can be produced either by HBV

179 e added to prevent access to epitopes on the surface antigens hemagglutinin (HA or H) and neuraminida

180 w antibodies that target the influenza virus surface antigens, hemagglutinin (HA) (including head and

181 DNA serum levels or antibody to hepatitis B surface antigen/hepatitis B surface antigen seroreversio

182 were also able to detect antibodies to these surface antigens in C abortus-infected women who had und

183 e removal efficiency of hepatitis B core and surface antigens in cascades of continuous flow microbia

184 ttractive vaccine candidates as they present surface antigens in their natural context.

185 itis B virus (HBV; based on detection of HBV surface antigen) in people who inject drugs (PWID), by g

186 Cell surface antigens, in addition to HLA, may serve as the s

187 ic antibodies of different valencies to cell surface antigens including MET and EGF receptor, we have

188 Moreover, we could immunophenotype EV surface antigens, including directly in blood and plasma

189 za hemagglutinin (HA) and neuraminidase (NA) surface antigens increase in the weeks after infection o

190 e kinase such as orphan receptor 1 (Ror1), a surface antigen, is a member of the RTK family of Ror, w

191 is manifested by the expression of the cell surface antigen known as epithelial cell adhesion molecu

192 s GALE (-/-) cells exhibited FS-7-associated surface antigen ligand-induced apoptosis.

193 HBV functional cure is sustained hepatitis B surface antigen loss and anti-HBs gain, with normalizati

194 hepatitis B e-antigen (HBeAg) or hepatitis B surface antigen loss or seroconversion; the numbers need

195 The weighted probability of hepatitis B surface antigen loss was 2.0%.

196 As a common surface antigen, LPS is recognized by host immune cells,

197 table vaccine-induced antibodies against HBV surface antigen (<10 mIU/mL) among high-risk adults from

198 IV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or

199 IV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or

200 erent forms including overexpressed proteins/surface antigens, metabolites, miRNA, and the entire cel

201 iving donors and estimated all possible cell surface antigens mismatches for a given donor/recipient

202 nfected sheep developed mainly antibodies to surface antigens (MOMP, MIP, Pmp13G), all of which did n

203 atients with resolved infection (hepatitis B surface antigen negative) receiving chemotherapy for hem

204 surface antibody (anti-HBs) <10 IU/mL in HBV surface antigen-negative patients and negative IgG to ot

205 ence analyses of the influenza A virus (IAV) surface antigen neuraminidase (NA or N) showed that the

206 e switching from the ubiquitous SAG1 to rare surface antigens not previously observed in tachyzoites.

207 t can directly be used for detection of cell surface antigens obviating the laborious steps of protei

208 scribing genetic redirection of T cells to a surface antigen of choice.

209 ERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in

210 PfEMP1 is the major surface antigen of P. falciparum-infected erythrocytes,

211 of circumsporozoite protein (CSP), the major surface antigen of Plasmodium falciparum (Pf) sporozoite

212 ecifically proposed in relation to the major surface antigen of the blood stage, known as PfEMP1 and

213 expression of distinct variants of the major surface antigen of the blood stages known as Pf EMP1 enc

214 d a proteomics approach to identify 23 novel surface antigens of G. lamblia that show >90% amino acid

215 the evolution of antibodies to the dominant surface antigens of Plasmodium vivax and P. falciparum f

216 Several vaccine candidates targeting defined surface antigens of S. aureus have failed to meet clinic

217 d structural and biochemical analysis of the surface antigens of the virus.

218 A specific surface antigen, OmpD has been reported first time as a

219 lyfish-derived allergen showed expression of surface antigens on basophils increased in a concentrati

220 xins (antibody-toxin fusion proteins) target surface antigens on cancer cells and kill these cells vi

221 r-to-year variation in immune recognition of surface antigens on CGS parasite-infected erythrocytes.

222 unknown whether autoantibodies against cell-surface antigens on human RPCs exist in DR patients, whe

223 we generated DVD-ARCs targeting various cell surface antigens on multiple myeloma cells for the selec

224 1b, if they tested positive for hepatitis B surface antigen or anti-HIV antibody at screening, or if

225 ncorporation of a spacer-into the mesothelin surface antigen or the cancer drug itself-converted SS-T

226 ; 95% CI: 1.09-1.40; P = 0.001), hepatitis B surface antigen, or anti-hepatitis C virus positivity (O

227 jects with positive serology for hepatitis B surface antigen (P for trend = 0.02).

228 culating autoantibodies against the podocyte surface antigens phospholipase A2 receptor 1 (PLA2R1) an

229 ified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we described LSM

230 ntibody positive, 85 (7.4%) were hepatitis B surface antigen positive, and 17 (1.5%) were anti-HDV po

231 tibody positive, and 9.0% (5.1-13.2) are HBV surface antigen positive; there is substantial geographi

232 ally exclusive pattern was found between HBV surface antigen-positive (HBsA-positive) and HBV DNA- an

233 Participants were anti-HIV/hepatitis B surface antigen-positive adults from eight clinical site

234 association became stronger for hepatitis B surface antigen-positive persons who also had low serum

235 eening; its application to the Mongolian HBV surface antigen-positive population reveals an apparent

236 Those who are found to be hepatitis B surface antigen-positive should start appropriate antivi

237 The HBV surface antigen positivity prevalence was 0.4% (95% CI 0

238 unodeficiency virus coinfection, hepatitis B surface antigen positivity, cirrhosis, and HCC at baseli

239 th human immunodeficiency virus, hepatitis B surface antigen positivity, hepatocellular carcinoma, or

240 ease, testing positive for hepatitis B virus surface antigen, pregnancy, creatinine clearance less th

241 anoparticles by lymphoma cells with distinct surface antigens pretreated with different bispecific st

242 that a virus containing a hemagglutinin (HA) surface antigen previously unseen by a majority of the p

243 e report single-cell transcriptomes and cell surface antigen profiles of over 24,000 cells from high

244 hematically predicted that a highly variable surface antigen prolongs bacterial infection sufficientl

245 demonstrate that identification of conserved surface antigens provides a powerful approach for overco

246 cells (OPCs) that are positive for the cell surface antigen recognized by the O4 antibody (O4(+)) ap

247 imated overall seroprevalence of hepatitis B surface antigen remains high at 6.1% (95% uncertainty in

248 with CPD-MAGE-A3 did not alter specific cell-surface antigens required for T-cell activation.

249 A major surface antigen, rickettsial outer membrane protein A (r

250 Monoclonal antibodies target these leukemic surface antigens selectively and minimize off-target tox

251 chemokine-receptor signaling, or that target surface antigens selectively expressed on CLL cells, pro

252 The cumulative rate of hepatitis B surface antigen seroclearance at 1, 5, and 10 years was

253 dence rates of HBV infection and hepatitis B surface antigen seroclearance were estimated after takin

254 To achieve functional cure (ie, HBV surface antigen seroclearance) and complete cure (ie, er

255 ronic carriers, and the rates of hepatitis B surface antigen seroclearance.

256 Patients with positive anti-hepatitis B surface antigen serology were excluded.

257 duced MTCT, as defined by infant hepatitis B surface antigen seropositivity (risk ratio = 0.3, 95% co

258 y to hepatitis B surface antigen/hepatitis B surface antigen seroreversion.

259 ns in HBV core, preS2, and small hepatitis B surface antigen (SHB) were more frequent in patients wit

260 Most autoantibodies against neuronal surface antigens show robust effects on the target prote

261 gets such as cancer cells with other special surface antigens, significant biological small molecules

262 eukin 10, or interleukin 6 production by HBV surface antigen-specific T cells.

263 the high cancer-specific expression of cell surface antigens such as mesothelin, which is overexpres

264 magglutinin (HA) glycoprotein is the primary surface antigen targeted by the host immune response and

265 , we identified a highly specific tumor cell surface antigen that can be targeted for therapy develop

266 ic targets and functions of antibodies to IE surface antigens that protect against severe malaria is

267 pairs, dimerized by hinge domains, bound to surface antigens that support a platform of Fc regions.

268 odies, each corresponding to a specific cell-surface antigen, that have been functionalized in a sing

269 ed on the hemagglutinin, but the other major surface antigen, the neuraminidase, has reemerged as a p

270 ram-negative cell envelope and a unique cell surface antigen; therefore, this approach should be gene

271 WTA can act as a cloak to limit exposure of surface antigens to the immune system, but this report i

272 mice, and in mice that carried a hepatitis B surface antigen transgene-this to model the multiplicati

273 Oncogenic surface antigen truncation mutations were detected in en

274 and the absence of hematopoietic or myeloid surface antigens; (v) self-renewal potential displayed b

275 evealed a peculiar enrichment of hepatitis B surface antigen vaccine-escape mutations that could have

276 Plasmodium falciparum parasites express the surface antigen VAR2CSA, which mediates adherence of red

277 is by removing the glycan moieties from cell surface antigens via enzymatic digestion, a process term

278 in the mammalian host (e.g., mice) due to a surface antigen, VlsE.

279 anosomiasis and regularly switches its major surface antigen, VSG, thereby evading the host's immune

280 T. brucei regularly switches its major surface antigen, VSG, to evade the host immune responses

281 ne response by regularly switching its major surface antigen, VSG, which is expressed exclusively fro

282 Prevalence of hepatitis B surface antigen was 8% (48 of 574) and hepatitis C antib

283 Antibody to hepatitis B surface antigen was tested 1 month after the third vacci

284 HBV infection (hepatitis B surface antigen) was diagnosed with serological assays.

285 alciparum EMP-1 (PfEMP-1) is a major variant surface antigen, we used var Ups quantitative reverse tr

286 s in Cohort B without detectable hepatitis B surface antigen were assigned by blocked randomisation t

287 nd B2, and those with detectable hepatitis B surface antigen were assigned to cohort B3.

288 inically significant changes in levels of HB surface antigen were observed.

289 Antibodies to IE surface antigens were examined in a case-control study o

290 acy of the immune response to B. burgdorferi surface antigens were monitored via a superinfection mod

291 2], MSP-119, and the infected red blood cell surface antigens were not.

292 d cell-based assays with known neuronal cell-surface antigens were used.

293 ecificity against tumor cells expressing two surface antigens while avoiding off-target recognition o

294 emphasized for the detection of viral RNAs, surface antigens, whole viral particles, antibodies and

295 identify ALPP2 as a true tumor-specific cell surface antigen whose tissue specificity enables the dev

296 eduction in serum viral load and reduced WHV surface antigen (WHsAg) levels to below the limit of det

297 aracterized by sustained loss of hepatitis B surface antigen with or without hepatitis B surface anti

298 To identity novel mesothelioma cell surface antigens with broad subtype coverage and high ti

299 erapy is limited by the availability of cell surface antigens with sufficient cancer-specific express

300 se and cell membrane proteins, including the surface antigen WspA, a peptidoglycan-associated lipopro